My personal belief is that the impressive safety profile and seemingly universal efficacy of Brilacidin will blow away the competition in multiple instances. A successful B-CV19 human trial will be the catalyst as the first FDA fully approved instance. This will pave the way for a multitude of instances including the very large and extremely lucrative Ulcerative Colitis market.

The referenced article on the Gilead filgotinib drug study demonstrates the delicate balance that most other drugs face across various instances and markets. In this example regarding safety and efficacy it took the highest dose of 200mg with a subset of patients that had not tried biologic drugs to get a 26% improvement vs a 15% on placebo. The safety profile had a lower percentage of overall safety issues versus current IBD alternative drugs but those affected included serious infections, herpes zoster and pulmonary embolism. The side effects of other JAK1 inhibitors are even more prevalent and come with a black box warning.

The IBD market is huge at an estimated $48B and there are many Big Pharmaceutical companies anxious to grab a piece of this lucrative market share. The safety and efficacy profile of Brilacidin will be again proven in the upcoming B-CV19 human trials and again next year in a phase2 B-IBD UC trial using the BDD pill technology. I believe Big Pharma will be aggressively pursuing a partnership with IPIX at that point. I also believe Brilacidin will become a true franchise drug, meaning it will be marketed across a multitude of markets as a treatment for many instances of disease with multiple IPIX partners. The US government IMO will be the first of these partners with B-CV19.